ARCT
Arcturus Therapeutics Holdings Inc.
$7.60
+0.25 (+3.40%)
At close · Jul 7
Market Cap
$216.02M
Shares
28,423,069
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.60
Open$7.34
Day$7.30–7.67
52W$5.85–24.17
Avg vol 30d426K
Short int6.7M · 23.6% float · 17.7d
Short vol61%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−17%
below
Price vs 50-day avg
−0%
below
RSI (14)
57
neutral
MACD trend
Positive
52-week position
10%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
+1%
trailing
YTD return
+24%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
3 of 125 funds reported for Jun 30 · net +66.9K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.60% of float · ▼ -0.3% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
125 holders — near 3-yr low, contrarian setup
Squeeze score
88
high risk · 0–100
Fundamentals
Revenue growth
−46%
Y/Y
EPS growth
+20%
Y/Y
Free cash flow
$-74.5M
Balance sheet
$215.6M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−75%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−17%
Bearish
Price vs 50-day avg
−0%
Neutral
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
10%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
3 of 125 funds reported for Jun 30 · net +66.9K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
23.60% of float · ▼ -0.3% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
125 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $6
Now $8 · 10%
52-wk high $24
vs 200-day avg -17%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARCT
this stock
Arcturus Therapeutics Holdings Inc.
|
$216.02M | +24.0% | -46.1% | — | 23.6% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.55B | +15.2% | +46.2% | 31.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.90B | -12.3% | +20.8% | 16.5 | 3.2% |
|
ARGX
Argenx SE
|
$57.49B | +9.4% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARCT | +13.6% | +4.1% | +0.9% | +13.1% | +24.0% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +12.7% | +2.7% | -6.6% | +13.0% | +14.3% |